Analysts expect Quotient Limited (NASDAQ:QTNT) to report $-0.51 EPS on May, 28.They anticipate $0.18 EPS change or 26.09% from last quarter’s $-0.69 EPS. After having $-0.47 EPS previously, Quotient Limited’s analysts see 8.51% EPS growth. The stock decreased 1.68% or $0.08 during the last trading session, reaching $4.69. About 173,228 shares traded. Quotient Limited (NASDAQ:QTNT) has declined 24.44% since May 16, 2017 and is downtrending. It has underperformed by 35.99% the S&P500.
Clover Partners Lp decreased Territorial Bancorp Inc (TBNK) stake by 62.82% reported in 2017Q4 SEC filing. Clover Partners Lp sold 181,173 shares as Territorial Bancorp Inc (TBNK)’s stock declined 4.14%. The Clover Partners Lp holds 107,224 shares with $3.31M value, down from 288,397 last quarter. Territorial Bancorp Inc now has $279.46 million valuation. The stock increased 0.73% or $0.22 during the last trading session, reaching $30.35. About 12,310 shares traded. Territorial Bancorp Inc. (NASDAQ:TBNK) has declined 2.35% since May 16, 2017 and is downtrending. It has underperformed by 13.90% the S&P500.
Among 3 analysts covering Quotient (NASDAQ:QTNT), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Quotient had 6 analyst reports since August 11, 2015 according to SRatingsIntel. The stock has “Buy” rating by BTIG Research on Tuesday, February 6. On Friday, August 14 the stock rating was upgraded by Zacks to “Hold”. The rating was initiated by BTIG Research on Thursday, August 31 with “Buy”. The stock has “Buy” rating by Jefferies on Tuesday, August 11. The rating was maintained by Jefferies on Wednesday, November 1 with “Buy”. The firm earned “Buy” rating on Wednesday, November 4 by UBS.
Quotient Limited, a commercial-stage diagnostics company, develops, makes, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company has market cap of $213.81 million. The firm is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening. It currently has negative earnings. It also develops, makes, and commercializes conventional reagent products for blood grouping, including antisera products that are used to identify blood-group antigens; reagent red blood cells, which enable the identification of blood-group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping.
Investors sentiment increased to 1.93 in 2017 Q4. Its up 0.51, from 1.42 in 2017Q3. It improved, as 5 investors sold Quotient Limited shares while 10 reduced holdings. 7 funds opened positions while 22 raised stakes. 30.23 million shares or 41.49% more from 21.37 million shares in 2017Q3 were reported. Manufacturers Life Ins Co The invested in 0% or 4,939 shares. Citigroup reported 3,157 shares. 59,700 are held by Birchview Capital Lp. Tower Rech Capital Lc (Trc) has invested 0% in Quotient Limited (NASDAQ:QTNT). Park West Asset Mngmt Limited Company accumulated 0.07% or 300,087 shares. Cormorant Asset Mgmt Ltd Llc stated it has 4.49 million shares or 2.33% of all its holdings. Bnp Paribas Arbitrage invested in 0% or 5,591 shares. Ameritas Inv Ptnrs invested 0% in Quotient Limited (NASDAQ:QTNT). Barclays Pcl has 59,014 shares for 0% of their portfolio. Parallax Volatility Advisers Ltd Partnership holds 0% or 4,074 shares in its portfolio. Geode Mgmt Ltd invested in 75,232 shares or 0% of the stock. Ameriprise Fin Incorporated holds 0% or 2.15M shares in its portfolio. Parametric Portfolio Associate Lc holds 10,194 shares. Jpmorgan Chase And Communication owns 5,768 shares. Moreover, Perceptive Lc has 0.98% invested in Quotient Limited (NASDAQ:QTNT).
Since February 21, 2018, it had 1 insider purchase, and 0 selling transactions for $51,348 activity. 12,000 Quotient Limited (NASDAQ:QTNT) shares with value of $51,348 were bought by von Prondzynski Heino.
More news for Quotient Limited (NASDAQ:QTNT) were recently published by: Globenewswire.com, which released: “Quotient Limited to Report Fourth Quarter and Fiscal Full Year 2018 Financial Results and Host Conference Call” on May 15, 2018. Streetinsider.com‘s article titled: “Quotient (QTNT) Announces FDA Approval of Seven Blood Bank Reagents, Including Two Market Firsts” and published on April 24, 2018 is yet another important article.
Investors sentiment decreased to 1.23 in 2017 Q4. Its down 0.04, from 1.27 in 2017Q3. It is negative, as 5 investors sold TBNK shares while 25 reduced holdings. 14 funds opened positions while 23 raised stakes. 4.05 million shares or 2.91% less from 4.17 million shares in 2017Q3 were reported. Brandes Investment Prtnrs Limited Partnership has 47,218 shares for 0.03% of their portfolio. Alliancebernstein Limited Partnership holds 0% or 73,923 shares. Parallax Volatility Advisers LP reported 1,218 shares stake. Jacobs Levy Equity holds 0.01% of its portfolio in Territorial Bancorp Inc. (NASDAQ:TBNK) for 11,882 shares. Stone Ridge Asset Management Ltd holds 0.02% or 9,116 shares in its portfolio. Ameritas Invest Ptnrs holds 665 shares. Bessemer Gp holds 0% or 11,800 shares. 8,818 were accumulated by Rhumbline Advisers. Amer Intll Group Inc accumulated 5,194 shares. Dimensional Fund Advsr Ltd Partnership has 457,469 shares for 0.01% of their portfolio. Barclays Pcl owns 1,422 shares or 0% of their US portfolio. Tower Lc (Trc) owns 1,157 shares. Legal & General Grp Inc Pcl owns 1,982 shares for 0% of their portfolio. Federated Invsts Pa has invested 0.01% in Territorial Bancorp Inc. (NASDAQ:TBNK). Thrivent Financial For Lutherans holds 45,493 shares or 0% of its portfolio.
Another recent and important Territorial Bancorp Inc. (NASDAQ:TBNK) news was published by Nasdaq.com which published an article titled: “Territorial Bancorp Inc. Declares Dividend” on April 26, 2018.
Since February 23, 2018, it had 0 insider purchases, and 1 sale for $114,292 activity. On Friday, February 23 the insider Ikeda Howard Y sold $114,292.